CE·Celanese Corporation

Celanese Corporation is a global manufacturer of engineered polymers and acetyl products, operating through Engineered Materials and Acetyl Chain segments that serve automotive, medical, consumer electronics, and construction markets. In the last two quarters, Celanese posted EPS of $1.45 in Q4 2024 and $0.57 in Q1 2025, both above estimates of $1.20 and $0.39 respectively, while revenue rose to $2.37 billion and $2.389 billion. The following quarters saw EPS of $1.44 in Q2 2025 and $1.34 in Q3 2025, again beating forecasts of $1.40 and $1.22, with revenue climbing to $2.532 billion and $2.419 billion. However, Q4 2025 EPS fell to $0.67 versus an estimate of $0.94 and revenue dipped to $2.204 billion, before rebounding to $0.85 in Q1 2026 and $2.45 in Q2 2026, both near or above estimates of $0.875 and $2.30, and revenue grew to $2.337 billion and $2.752 billion. Over the past year, Celanese has consistently beaten earnings estimates in six of seven quarters, with revenue growth of 8.7 % YoY in Q2 2025, though the Q4 2025 revenue decline highlights volatility in specialty‑chemicals demand. Recent news indicates that management cut Q3 guidance after a Q2 revenue shortfall, while a court dismissal of Shell and Repsol claims removed a significant liability and may free capital for expansion; analysts have lowered price targets amid concerns over margin compression. Investors should watch for the updated Q3 guidance, revenue and gross‑margin details, and any cost‑control initiatives that could translate the current demand resilience into improved profitability. The company’s revenue trajectory has been largely upward, with a 8.7 % YoY increase in Q2 2025 and a modest 4.5 % rise in Q1 2026, though the Q4 2025 dip reflects weaker specialty‑chemicals demand. EPS growth has accelerated from $1.45 in Q4 2024 to $2.45 in Q2 2026, underscoring effective cost management. The recent court ruling eliminating Shell and Repsol claims reduces potential legal expenses and may improve future profitability, while analysts’ target cuts signal caution over margin pressure. Investors should monitor the revised Q3 guidance for revenue, gross margin, and cost‑control initiatives, as well as upcoming demand data for specialty chemicals and engineered materials, to gauge whether the company can sustain its earnings momentum.